Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for amrn
1.95
+0.03 (1.56%)
After Hours: 1.96 +0.01 (0.51%)
May 27, 7:30PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.89 - 1.98
52 week 0.78 - 3.33
Open 1.93
Vol / Avg. 1.46M/1.89M
Mkt cap 347.30M
P/E     -
Div/yield     -
EPS -0.37
Shares 176.25M
Beta 0.71
Inst. own 36%
Aug 5, 2015
Q2 2015 Amarin Corporation PLC Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 7, 2015
Amarin Corporation PLC Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Jun 2, 2015
Amarin Corporation PLC at Jefferies Global Healthcare Conference - 8:00AM EDT - Add to calendar
May 8, 2015
Q1 2015 Amarin Corporation PLC Earnings Release
May 8, 2015
Q1 2015 Amarin Corporation PLC Earnings Call
Mar 3, 2015
Q4 2014 Amarin Corporation PLC Earnings Call
Mar 3, 2015
Q4 2014 Amarin Corporation PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -195.36% -103.99%
Operating margin -169.77% -106.86%
EBITD margin - -175.47%
Return on average assets -64.61% -26.61%
Return on average equity - -
Employees 201 -
CDP Score - -

Address

2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
DUBLIN, FK7 9JQ
Ireland
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amarin Corporation plc is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company’s lead product, Vascepa (known in its development stage as AMR 101), reduces triglyceride levels in adult patients with severe hypertriglyceridemia. The Company is developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels, referred as mixed dyslipidemia. REDUCE-IT is a multi-center, prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effectiveness of Vascepa. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in an at-risk patient population also receiving statin therapy. The Company completed dosing of AMR102, a fixed dose combination of Vascepa and a leading statin product.

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 54
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Age: 52
Bio & Compensation  - Reuters
Michael J. Farrell Vice President - Finance (principal accounting officer and principal financial officer)
Age: 37
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 52
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Non-Executive Independent Director
Age: 50
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 73
Bio & Compensation  - Reuters
Kristine Peterson Non-Executive Independent Director
Age: 55
Bio & Compensation  - Reuters